Skip to main content

Health condition · Clinically reviewed

Invasive lobular carcinoma, a distinct subtype with its own imaging, surgical and endocrine playbook.

ILC is not just breast cancer with a different label. It behaves differently, hides differently on scans and responds differently to treatment. Knowing the difference matters.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, NCCN and peer-reviewed breast oncology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including CDK4/6 inhibitors, PI3K inhibitors and next-generation SERDs.

Key facts

ILC at a glance.

The essentials, in plain English - what makes lobular different from ductal cancer, and why that difference shapes the whole care plan.

  • What it is

    A distinct histological subtype of breast cancer arising from the lobules, with a single-file infiltrative growth pattern driven by loss of E-cadherin.

  • How common

    The second most common invasive breast cancer, accounting for around 10 to 15 per cent of cases in the UK.

  • Molecular signature

    Almost always oestrogen and progesterone receptor positive, HER2 negative, and typically luminal A on molecular profiling.

  • Presentation

    Often a subtle area of thickening rather than a discrete lump, and frequently multifocal or bilateral at diagnosis.

  • Imaging

    MRI is more sensitive than mammography for ILC because the diffuse growth pattern can hide behind normal-looking dense tissue.

  • Genetics

    Germline CDH1 mutations link ILC to hereditary diffuse gastric cancer and warrant specialist genetics input.

Why this guide matters

A different cancer needs a different plan.

Lobular breast cancer is often treated as if it were ductal. It isn’t. The three points below shape everything else on this page.

  • It hides on mammograms

    The single-file infiltrative pattern means ILC can be mammographically occult. MRI is more sensitive and is used routinely for extent-of-disease assessment.

  • Endocrine therapy is the backbone

    Almost all ILC is oestrogen and progesterone receptor positive. Long-course tamoxifen or an aromatase inhibitor is the single most important intervention.

  • Targeted therapy has caught up

    CDK4/6 inhibitors, PI3K inhibitors and next-generation SERDs give patients with hormone-driven ILC more options than ever, particularly in advanced disease.

How the diagnosis is made

From a subtle change to a clear MDT plan.

The steps a UK breast unit will normally follow, in order - so you know what to expect and why lobular disease sometimes needs a different pathway.

  1. 01

    Assessing

    Triple assessment

    Clinical examination, imaging and needle biopsy performed together at a specialist commissioned breast unit.

  2. 02

    Assessing

    Mammography and ultrasound

    Standard first-line imaging, though ILC can be mammographically occult because of its diffuse, single-file pattern.

  3. 03

    Assessing

    Breast MRI

    More sensitive than mammography for lobular disease, used routinely to assess extent, multifocality and the contralateral breast.

  4. 04

    Confirming

    Core biopsy and E-cadherin

    Histology confirms the lobular pattern and immunohistochemistry shows loss of E-cadherin, the diagnostic hallmark.

  5. 05

    Confirming

    Receptor and molecular profiling

    ER, PR and HER2 status guide systemic therapy. Most ILC is ER-positive, PR-positive and HER2-negative luminal A disease.

  6. 06

    Planning

    Staging imaging

    CT and, where indicated, PET-CT look for the unusual metastatic sites ILC favours, from peritoneum to gynaecological organs.

  7. 07

    Planning

    Specialist MDT and genetics

    A dedicated breast multidisciplinary team plans treatment. CDH1 germline testing is offered when family history suggests hereditary risk.

Typical timeline: from urgent referral to a settled MDT plan in weeks, not months.

Symptoms

What lobular breast cancer actually feels like.

Thickening rather than a lump, subtle changes rather than obvious ones - and a pattern of spread that doesn’t always look like other breast cancers.

  • Area of thickening

    A subtle, ill-defined firmness rather than a distinct lump - the classic lobular presentation.

  • Change in breast shape

    Retraction, flattening or a gradual change in size that a patient often notices before imaging does.

  • Nipple inversion or skin dimpling

    New nipple retraction or a pulling of the skin can be an early sign of underlying lobular disease.

  • Multifocal or bilateral disease

    ILC is more likely than ductal cancer to involve more than one area, and to affect both breasts.

  • Mammographically occult lesion

    Standard mammograms can miss ILC because the tumour cells infiltrate rather than form a mass.

  • Delayed diagnosis

    The subtle presentation means ILC is often larger at diagnosis than ductal cancer - a reason to trust persistent change.

  • Unusual metastatic pattern

    ILC has a distinct tendency to spread to peritoneum, gastrointestinal tract, gynaecological organs and bone marrow.

  • Red flag - persistent breast change

    Any persistent change in breast texture, shape or nipple position deserves prompt specialist assessment.

Treatment

How ILC is treated in the UK.

Surgery tailored to a diffuse pattern, radiotherapy where indicated, and the endocrine and targeted backbone that defines hormone-driven disease.

  • Surgery

    Mastectomy is often preferred for ILC because of its diffuse, multifocal pattern and the challenge of achieving clear margins. Specialist commissioned.

  • Contralateral prophylactic surgery

    Considered in CDH1 germline carriers or where imaging shows extensive bilateral change. A shared decision with the specialist team.

  • Radiotherapy

    Standard after breast-conserving surgery and often after mastectomy for node-positive or larger tumours. Specialist commissioned.

  • Endocrine therapy

    The mainstay of ILC care - tamoxifen or an aromatase inhibitor, typically for at least five and often ten years. Specialist commissioned.

  • CDK4/6 inhibitors

    Palbociclib, ribociclib or abemaciclib added to endocrine therapy in selected high-risk or advanced disease. See our CDK4/6 inhibitor clinic.

  • PI3K inhibitor (alpelisib)

    For PIK3CA-mutated, hormone receptor positive, HER2-negative advanced disease after endocrine progression. Specialist commissioned.

  • Next-generation SERDs

    Elacestrant, a selective oestrogen receptor degrader, is an emerging option in ESR1-mutated hormone-driven disease.

  • PARP inhibitors

    Olaparib for BRCA-mutated disease with high-risk features, offered through specialist commissioned pathways.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, international standards and lobular-specific patient organisations, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your breast MDT knows your imaging, histology and personal circumstances and can tell you which parts apply to you.

  • NICE. Early and locally advanced breast cancer: diagnosis and management (NG101).

  • NICE. Advanced breast cancer: diagnosis and treatment (CG81).

  • NCCN. Clinical Practice Guidelines in Oncology - Breast Cancer.

  • Lobular Breast Cancer UK and the Lobular Breast Cancer Alliance - patient and clinician resources.

Red flags

When breast changes need urgent attention.

Lobular disease is often subtle. These are the changes and situations where a specialist opinion should not wait.

  • Persistent breast thickening

    An area of new firmness that lasts more than a menstrual cycle deserves urgent specialist review, even without a discrete lump.

  • New nipple retraction

    Pulling-in of the nipple that was not there before is a classic ILC sign and warrants triple assessment.

  • Skin dimpling or texture change

    Any pulling, dimpling or peau d'orange should be seen quickly under the two-week suspected cancer pathway.

  • Unexplained abdominal or pelvic symptoms

    In a patient with a history of ILC, new bowel, pelvic or peritoneal symptoms deserve prompt investigation for unusual metastasis.

  • Family history of gastric cancer

    Diffuse gastric cancer in the family alongside lobular breast cancer raises the possibility of hereditary CDH1 syndrome.

  • Bone pain or new back pain

    Persistent skeletal pain in someone with a history of ILC should trigger imaging for bone or marrow involvement.

  • Neurological changes

    Rare but recognised - leptomeningeal spread can present with headache, cranial nerve symptoms or altered balance.

  • Rapid endocrine progression

    Loss of control on aromatase inhibitor therapy may signal ESR1 mutation and a role for a next-generation SERD such as elacestrant.

  • Contralateral breast change

    ILC has a higher rate of bilateral disease, so any new change in the opposite breast deserves urgent imaging.

Living with it

A hormone-driven cancer, managed for the long term.

Four things that make the biggest difference over the years - the right team, the endocrine backbone, structured surveillance and lobular-specific support.

A quiet reminder

Steady adherence beats occasional intensity.

With hormone-driven disease, the years of consistent endocrine therapy quietly do the heavy lifting.

  1. 01 Team

    Stay with a specialist breast MDT

    ILC benefits from a team that knows its quirks - imaging preferences, surgical planning and the endocrine backbone all matter.

  2. 02 Endocrine

    Take the endocrine therapy

    Long-course tamoxifen or an aromatase inhibitor is the single most important intervention. Side effects are manageable with your team.

  3. 03 Surveillance

    Keep up with follow-up imaging

    Because ILC can be subtle and bilateral, structured MRI-based follow-up is often part of the plan for higher-risk cases.

  4. 04 Community

    Use lobular-specific support

    Lobular Breast Cancer UK and the Lobular Breast Cancer Alliance offer information, peer support and advocacy tailored to ILC.

Frequently asked

Everything we get asked about lobular breast cancer.

Quick answers on imaging, genetics, endocrine therapy and the newer targeted options.

  • What is invasive lobular carcinoma?

    Invasive lobular carcinoma, or ILC, is a distinct subtype of breast cancer that begins in the milk-producing lobules. It accounts for around 10 to 15 per cent of invasive breast cancers and is defined by loss of the E-cadherin protein, which gives it a single-file, infiltrative growth pattern rather than a discrete lump.

  • How is ILC different from invasive ductal carcinoma?

    ILC tends to present as thickening rather than a mass, is more often multifocal and bilateral, is more commonly missed on mammography, and has a distinctive pattern of metastasis to the peritoneum, gastrointestinal tract, gynaecological organs and bone marrow. It is almost always oestrogen receptor positive, so endocrine therapy is central to treatment.

  • Why is MRI recommended for lobular breast cancer?

    The single-file growth pattern of ILC can be invisible or very subtle on mammography, especially in dense breast tissue. MRI is more sensitive at showing the true extent of disease and any additional foci in the same or the opposite breast, which is why it is used routinely in ILC work-up under specialist commissioning.

  • What is the role of CDH1 genetic testing?

    CDH1 germline mutations cause hereditary diffuse gastric cancer syndrome and also strongly predispose to lobular breast cancer. Where family history or clinical features suggest hereditary risk, specialist genetics teams offer CDH1 testing and, where positive, coordinate gastric surveillance and shared decisions about risk-reducing breast surgery.

  • Is neoadjuvant chemotherapy effective for ILC?

    ILC tends to respond less well to chemotherapy given before surgery than invasive ductal carcinoma. Response rates on imaging can be misleading, and the diffuse pattern makes assessment difficult. Neoadjuvant endocrine therapy is often a better fit for hormone-driven lobular disease and is used in specialist units.

  • What newer treatments are available for advanced ILC?

    Because ILC is almost always hormone-driven, the newer generation of endocrine and targeted drugs is highly relevant. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib are added to endocrine therapy in selected cases. The PI3K inhibitor alpelisib helps in PIK3CA-mutated disease, and next-generation SERDs like elacestrant are emerging for ESR1-mutated hormone-driven progression. PARP inhibitors have a role in BRCA-mutated disease. All are specialist commissioned.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.